From October 13 to 17, the International Biopharma Industry Week Shanghai 2025 was held in Shanghai, marking the fifth consecutive year that Shanghai has hosted this global platform. The theme of this year, "Global Linkage, Industrial Empowerment", accurately interprets Shanghai's pivotal role as a hub for collaborative development in the global biopharmaceutical landscape, serving as a source of innovation, a center for resource aggregation, and a point of regulatory convergence. Sino Biopharm (1177.HK), as one of the pharmaceutical companies actively investing in Shanghai, received attention from attending leaders and experts. During the event, Wu Wei, Member of the Standing Committee of the Shanghai Municipal Party Committee and Executive Vice Mayor, along with many guests, visited the booth of Sino Biopharm to hear a report from Mr. Eric Tse, Chief Executive Officer, on Sino Biopharm's investment and construction projects in Shanghai. 

Building a New R&D Highland: Chia Tai Tianqing's Global R&D Headquarters Nears Completion

With its favorable environment that supports innovation across the entire chain, Shanghai continues to attract top global scientific talent, startups, and multinational pharmaceutical giants. Chia Tai Tianqing, a core enterprise of Sino Biopharm, has also seized the development opportunity by investing RMB 1.8 billion in the construction of its global R&D headquarters in Shanghai. 

The global R&D headquarters, designed with the concept of "Life Ring + Cell Dissociation", connects four functional buildings via an innovative low-altitude circular corridor. It integrates R&D laboratories, headquarters offices, talent apartments, and industrial support facilities, aiming to create an international R&D community that stimulates innovation and gathers intelligence. The project is expected to be completed by the end of this year and will be officially put into use in the first half of 2026. It will then become a core engine for Sino Biopharm to strengthen its independent R&D capabilities and accelerate the transformation of innovative achievements. 

Driving the Transformation of Innovation Outcomes: Blockbuster Products and a Rich Pipeline

Garsorasib (Anfangning®) is the first Class 1 innovative drug to be marketed by Shanghai Chia-Tai Tianqing Pharmaceutical Technology Development Co., Ltd., the operating entity of global R&D headquarters project of Chia Tai Tianqing, under the Marketing Authorization Holder (MAH) system. Since its launch in November 2024, it has achieved sales of 167 million yuan, demonstrating excellent market potential. 

As a novel, efficient KRAS G12C inhibitor with innovative structural features, the rapid marketing of Garsorasib benefited from receiving both Breakthrough Therapy Designation and Priority Review status. Its first indication is for the treatment of patients with KRAS G12C-mutant advanced non-small cell lung cancer who have received at least one prior systemic therapy. Currently, Shanghai Chia-Tai Tianqing has also built an R&D pipeline containing more than ten monoclonal/bispecific antibodies, focusing on major disease areas such as neoplasm and autoimmune diseases, and has a reserve of innovative products with broad market prospects. 

Empowering the Industrial Ecosystem: Synergistic Efforts through Fund Establishment and Strategic M&A

To more precisely serve the biopharmaceutical industry and address common industry challenges such as "difficulty in financing, long cycles, and high risks", Sino Biopharm led the establishment of the "Sino Biopharm Leading (Shanghai) Private Investment Fund" in Pudong New Area, Shanghai, in April 2025, with a total size of RMB 1 billion. The fund will focus on investments in the biopharmaceutical field, aiming to accelerate the industry's development towards high-end, international, and clustered growth. 

In July 2025, Sino Biopharm announced the acquisition of LaNova Medicines Ltd. for a transaction consideration of up to US$951 million, which is seen by the industry as a model of complementary advantages and synergistic development between a leading pharmaceutical company and an innovative drug company. Through this acquisition, Sino Biopharm will effectively integrate the core assets of LaNova Medicines. Leveraging the industrialization and commercialization capabilities of Chia Tai Tianqing, LM-302, independently developed by LaNova Medicines, is expected to achieve a global first launch, to strengthen the competitiveness of Sino Biopharm in the global innovative drug market. 

Disclaimer:
1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes.
2. The company does not recommend any drugs and/or indications. 
3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific information about disease diagnosis and treatment, please follow the advice or guidance of a doctor or other healthcare professional. 
4. The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.